The telomeric PARP, tankyrases, as targets for cancer therapy
about
Tankyrase-1 assembly to large protein complexes blocks its telomeric functionRDX induces aberrant expression of microRNAs in mouse brain and liverIdentification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.Homogeneous screening assay for human tankyrase.Poly(ADP-ribose)polymerase inhibition decreases angiogenesis.ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosisPARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling PathwayTankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma.Advances in the proteomic discovery of novel therapeutic targets in cancer.Human telomerase expression regulation.Tankyrases as drug targets.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Tankyrases: structure, function and therapeutic implications in cancer.mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.RDX and miRNA Expression: Zhang and Pan Respond.Cross-species difference in telomeric function of tankyrase 1.Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.Propping up a destructive regime
P2860
Q24294752-D349F9EE-7604-4EF5-AE82-37491C6DF0C4Q24647072-374C1DC0-F9A1-486D-AAFA-521D3F983754Q33494714-D1860497-EB1A-453E-B3C7-7163E60A9A6BQ34167299-8BF80C13-AE8A-4DC4-AE36-E319DE74A569Q35676514-053107EB-A453-443B-B009-48A297093E7BQ36175526-EF33ACCC-5E8A-4FD8-A92A-67F0D331EF16Q36247467-F9A4D244-5564-4E18-9085-9EF0BED63C5AQ36905632-8307BA5C-E687-4809-89A5-CD16A99EF217Q37093551-08701407-781B-4035-9D28-4D7B36554792Q37260569-CCAF22BE-7CED-40CC-9695-1D5B63A8A45CQ37905799-951885E0-98DB-459F-8F72-54475956F822Q38104494-1F3C8A50-3C1F-4749-8E38-9C096AEEA773Q38191981-88050382-24E6-46C1-BB31-637BBDBB1A05Q38224266-3A54D668-718E-4FAD-8345-EF139A82925BQ38700323-182415CB-F676-465C-B238-8985A24FF0EAQ38872456-68385571-0264-4A74-9DE4-16F96963049CQ46535188-AB04459A-890A-479C-84F1-79C73AC237CDQ53334672-E9F76301-6556-4110-BBF4-DC3064B94EE9Q54062885-260C6549-740A-48B9-8F48-6A79811407ABQ74441562-C3FDA548-CD95-47A9-9651-EFCB418C34B6
P2860
The telomeric PARP, tankyrases, as targets for cancer therapy
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The telomeric PARP, tankyrases, as targets for cancer therapy
@ast
The telomeric PARP, tankyrases, as targets for cancer therapy
@en
type
label
The telomeric PARP, tankyrases, as targets for cancer therapy
@ast
The telomeric PARP, tankyrases, as targets for cancer therapy
@en
prefLabel
The telomeric PARP, tankyrases, as targets for cancer therapy
@ast
The telomeric PARP, tankyrases, as targets for cancer therapy
@en
P2860
P356
P1476
The telomeric PARP, tankyrases, as targets for cancer therapy
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602951
P407
P577
2006-02-01T00:00:00Z
2006-02-13T00:00:00Z